Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Starpharma Holdings Limited (ASX:SPL) SPL7013 Shows Activity Against All Major Clinically Relevant Human Papillomavirus (HPV) Strains

Abstract:
Starpharma Holdings Ltd (ASX:SPL)(OTCQX:SPHRY) today announced new data showing that SPL7013, the active ingredient in its topical microbicide VivaGel(R), inhibits all four strains of the human papillomavirus (HPV) targeted by the two marketed cervical cancer vaccines.

Starpharma Holdings Limited (ASX:SPL) SPL7013 Shows Activity Against All Major Clinically Relevant Human Papillomavirus (HPV) Strains

Melbourne, Australia | Posted on December 4th, 2008

These pre-clinical results extend those of a previous study showing that SPL7013 was active against two of the four strains targeted by the vaccines. SPL7013 has now been shown to have in vitro activity against HPV-16 and -18, which account for approximately 70% of cervical cancers; and HPV-6 and -11, which together account for approximately 90% of the incidence of genital warts.

In addition, the latest results demonstrate SPL7013 to be active against HPV-31. Previously SPL7013 has been demonstrated to be active against HPV-45. These two strains have been implicated in more than 4% of cervical cancers but neither is included in the existing vaccines.

Starpharma CEO, Dr Jackie Fairley said: "The new data support our earlier findings that VivaGel(R) may have potential for reducing the risk of genital HPV infection, the most common sexually transmitted infection in the United States."

"Showing that VivaGel(R) has activity against all major clinically relevant strains of HPV tested so far, in particular those strains not covered by the current cervical cancer vaccines, further strengthens the growing body of evidence demonstrating the efficacy of SPL7013 against several important STIs."

In the US, 6.2 million people are newly infected with HPV each year. HPV infection is a factor in the development of virtually all cases of cervical cancer.

VivaGel(R) is currently under clinical development as a vaginal microbicide for the prevention of transmission of HIV and genital herpes (HSV-2).

####

About Starpharma Holdings Ltd
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

For more information, please click here

Contacts:
Dr Jackie Fairley
Chief Executive Officer
TEL: +61-3-8532-2704

Ben Rogers
Company Secretary
TEL: +61-3-8532-2702

Copyright © Starpharma Holdings Limited

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

HP Supercomputer at NREL Garners Top Honor October 19th, 2014

First Canada Excellence Research Chair gets $10 million from the federal government for oilsands research at the University of Calgary: Federal government announces prestigious research chair to study improving oil production efficiency October 19th, 2014

Ucore's McKenzie to Deliver Presentation to Rare Earths Conference in Singapore as Highlight of Fall 2014 Marketplace Schedule October 19th, 2014

Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014

Nanomedicine

Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014

European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Tuning light to kill deep cancer tumors: Nanoparticles developed at UMass Medical School advance potential clinical application for photodynamic therapy October 15th, 2014

Announcements

HP Supercomputer at NREL Garners Top Honor October 19th, 2014

First Canada Excellence Research Chair gets $10 million from the federal government for oilsands research at the University of Calgary: Federal government announces prestigious research chair to study improving oil production efficiency October 19th, 2014

Ucore's McKenzie to Deliver Presentation to Rare Earths Conference in Singapore as Highlight of Fall 2014 Marketplace Schedule October 19th, 2014

Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE